A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > TOP STORIES
TOP STORIES
-
ORGANIZATION Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
-
BUSINESS “Appropriate Expressions” of Disease Awareness Ads Being Tested
January 7, 2013
-
ORGANIZATION Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
-
ORGANIZATION NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
-
REGULATORY 2nd Abe Cabinet Inaugurated; Industry Awaits Decision on Perpetuation of Premium for New Drug Development
December 27, 2012
-
REGULATORY LDP to Finalize Tax Reform Outline for FY2013 by Late January
December 26, 2012
-
ORGANIZATION JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
-
REGULATORY MHLW to Establish a Venue for Discussions to Review Policies for OTC Switching of Lifestyle Disease Treatments
December 21, 2012
-
REGULATORY Osaka’s Healthcare Plan Highlights Differences in Definition of “Frequent Deliveries”
December 21, 2012
-
REGULATORY CSIMC Recommends New Rules on Reducing Prices of Long-Listed Drugs
December 21, 2012
-
REGULATORY MHLW to Revise and Consider Legislation of Ethical Guidelines for Clinical Research
December 20, 2012
-
REGULATORY Pharmaceutical Industry Welcomes Incoming Abe Administration
December 19, 2012
-
BUSINESS Takeda Faces Generic Entry for Candesartan in US
December 18, 2012
-
BUSINESS Pfizer Specialty Care Chief Hopeful about Japan Vaccine Market, Novel RA Treatment
December 17, 2012
-
BUSINESS Elmed Eisai, Kobayashi Kako Get Their Allegra Generics Listed
December 14, 2012
-
BUSINESS Zydus to Build New Plant in India for Japan-Bound Generics
December 13, 2012
-
REGULATORY Strategy Council Proposes Revamped Framework to Oversee Entire Life Innovation Budgets
December 12, 2012
-
BUSINESS Mochida Revving Up Collaboration Efforts in Biosimilars
December 11, 2012
-
REGULATORY Long-Listed Products Not Granted Premium Should Be Exempted from New Rule: FPMAJ’s Kamoya
December 10, 2012
-
BUSINESS Actavis Eyes 3 Monoclonal Antibodies for Entry into Japanese Biosimilar Market: EVP
December 10, 2012
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…